SWOT Analysis

Strengths: High efficacy and specificity of immunotherapy, Reduced side effects compared to chemotherapy, Rising popularity of targeted therapies.
Weaknesses: High development cost of novel drugs, Requirement of combination therapy, Challenges in patient selection.
Opportunities: Increasing incidence of cancer worldwide, Growing healthcare expenditure, Robust pipeline of immunotherapies.
Threats: Intensive regulatory procedures, Reimbursement policies, Technical challenges in drug development.

Key Takeaways

The Global Immunotherapy Drugs Market Size is expected to witness high growth, exhibiting CAGR of 11.5% over the forecast period, due to increasing demand for targeted therapies. The market size in 2023 is US$ 188.9 Bn.

Regional analysis: North America dominates the global immunotherapy drugs market owing to new product approvals, developed healthcare infrastructure and availability of reimbursements. Asia-Pacific is expected to witness the fastest growth over the forecast period due to rising affordability, growing cases of cancer and increasing adoption of advanced therapeutics.

Key players operating in the Immunotherapy Drugs market are F. Hoffmann-La Roche AG, Merck Group, Bristol Myers Squibb, GlaxoSmithKline, AstraZeneca, Novartis, Janssen Pharmaceuticals, among others. Key players are focusing on developing combination therapies by combining immunotherapy with chemotherapy, targeted therapy and other treatment modalities to improve therapeutic efficacy.

Read More -  https://justpaste.me/vbIv2